Adam Friedman, Scorpion Therapeutics CEO

Scor­pi­on rais­es $150M with sights on the next wave of tar­get­ed ther­a­pies

Scor­pi­on Ther­a­peu­tics has a fresh $150 mil­lion to work with as it moves an ex­per­i­men­tal breast can­cer drug through clin­i­cal tri­als in an ef­fort to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA